Precision BioSciences does not distribute cash dividends to its common shareholders. As an emerging clinical-stage biotechnology enterprise operating in the capital-intensive gene-editing sector, the company preserves its financial cash reserves to fund ongoing research and development programs, preclinical studies, and clinical trials rather than returning capital through dividend distributions.